PARIS, Jan 8, 2026, 20:02 (CET) — Market closed
Shares in French biotech Abivax SA (ABVX.PA) closed down 9.49% at 99.20 euros on Thursday, after swinging between 112.40 euros at the open and a low of 94.20 euros. The stock slipped back under the 100-euro mark, with volume at about 246,000 shares, after a 6% rise the day before.
The selling pressure comes as investors look ahead to key readouts for obefazimod, Abivax’s lead drug candidate for ulcerative colitis, a chronic inflammatory bowel disease. Abivax has told investors topline results from its Phase 3 maintenance study are expected in late Q2 2026, with a U.S. regulatory filing planned later in 2026.
With no marketed product, the stock trades on milestones and sentiment. Fresh supply from big holders can move it fast, even on days with little new clinical data.
A U.S. Form 144 filing showed shareholder Sofinnova Crossover I SLP intends to sell up to 1,000,000 American depositary shares (ADS) through Leerink Partners on Nasdaq, with an indicated aggregate market value of $133.7 million. Rule 144 is an SEC rule that sets conditions for resales of restricted or “control” stock; a notice signals intent but does not guarantee a sale. Stock Titan
BTIG analyst Julian Harrison raised his price target on Abivax to $150 from $120 and kept a “Buy” rating, according to a report published on Thursday. GuruFocus
But the same setup that fuels sharp rallies can cut the other way. If more stock hits the market, it can cap rebounds, and any slip in trial timelines — or an efficacy or safety disappointment — would likely reset expectations quickly.
